(1) Elderly and high COVID-age population: 1. Age < 18 years 2. Prior or concurrent treatment for COVID-19 (unless listed as authorized specific treatment in section VII.7) 3. History of COVID-19 disease 4. Prior anti-SARS-CoV-2 immunization 5. Contraindication to receiving CCP including previous history of transfusion-related acute lung injury (TRALI) or moderate or severe allergic reaction to blood components 6. Known participant objection to receiving plasma products 7. Primary or acquired immune deficiency listed below (see cohort 2) 8. Refusal to participate expressed by patient or legally authorised representative 9. Pregnancy (2) High-risk immunocompromised population 1. Age < 18 years 2. Prior or concurrent treatment for COVID-19 (dexamethasone, anti-IL-6/IL6R, remdesivir) except for prophylactic administration of anti-SARS-Cov2 monoclonal antibodies (pre or post exposure) in cohort 2 and authorized specific treatnebt in section VII.7) 3. History of COVID-19 disease 4. Contraindication to receiving CCP including previous history of transfusion-related acute lung injury (TRALI) or moderate or severe allergic reaction to blood components 5. Known participant objection to receiving plasma products 6. Refusal to participate expressed by patient or legally authorised representative 7. Pregnancy Enrolment in other trials after reaching the primary end-point is authorised.

(1) Elderly and high COVID-age population: 1. Age < 18 years 2. Prior or concurrent treatment for COVID-19 (unless listed as authorized specific treatment in section VII.7) 3. History of COVID-19 disease 4. Prior anti-SARS-CoV-2 immunization 5. Contraindication to receiving CCP including previous history of transfusion-related acute lung injury (TRALI) or moderate or severe allergic reaction to blood components 6. Known participant objection to receiving plasma products 7. Primary or acquired immune deficiency listed below (see cohort 2) 8. Refusal to participate expressed by patient or legally authorised representative 9. Pregnancy (2) High-risk immunocompromised population 1. Age < 18 years 2. Prior or concurrent treatment for COVID-19 (dexamethasone, anti-IL-6/IL6R, remdesivir) except for prophylactic administration of anti-SARS-Cov2 monoclonal antibodies (pre or post exposure) in cohort 2 and authorized specific treatnebt in section VII.7) 3. History of COVID-19 disease 4. Contraindication to receiving CCP including previous history of transfusion-related acute lung injury (TRALI) or moderate or severe allergic reaction to blood components 5. Known participant objection to receiving plasma products 6. Refusal to participate expressed by patient or legally authorised representative 7. Pregnancy Enrolment in other trials after reaching the primary end-point is authorised.